RESEARCH ARTICLE

Network pharmacology of bioactives from *Sorghum bicolor* with targets related to diabetes mellitus

Ki Kwang Oh, Md. Adnan, Dong Ha Cho *

Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea

* chodh@kangwon.ac.kr

Abstract

**Background**

*Sorghum bicolor* (SB) is rich in protective phytoconstituents with health benefits and regarded as a promising source of natural anti-diabetic substance. However, its comprehensive bioactive compound(s) and mechanism(s) against type-2 diabetes mellitus (T2DM) have not been exposed. Hence, we implemented network pharmacology to identify its key compounds and mechanism(s) against T2DM.

**Methods**

Compounds in SB were explored through GC-MS and screened by Lipinski’s rule. Genes associated with the selected compounds or T2DM were extracted from public databases, and the overlapping genes between SB-compound related genes and T2DM target genes were identified using Venn diagram. Then, the networking between selected compounds and overlapping genes was constructed, visualized, and analyzed by RStudio. Finally, affinity between compounds and genes was evaluated via molecular docking.

**Results**

GC-MS analysis of SB detected a total of 20 compounds which were accepted by the Lipinski’s rule. A total number of 16 compounds-related genes and T2DM-related genes (4,763) were identified, and 81 overlapping genes between them were selected. Gene set enrichment analysis exhibited that the mechanisms of SB against T2DM were associated with 12 signaling pathways, and the key mechanism might be to control blood glucose level by activating PPAR signaling pathway. Furthermore, the highest affinities were noted between four main compounds and six genes (FABP3-Propyleneglyco monoleate, FABP4-25-Oxo-27-norcholesterol, NR1H3-Campest erol, PPARA-β-sitosterol, PPARD-β-sitosterol, and PPARG-β-sitosterol).
Conclusion

Our study overall suggests that the four key compounds detected in SB might ameliorate T2DM severity by activating the PPAR signaling pathway.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a metabolic disease triggered by the complex interaction between genetic and/or environmental associations. Patients with T2DM have either insulin resistance (sugar transfer dysregulation into cells) or lack of optimal insulin secretion to sustain natural glucose levels [1]. T2DM can affect at all ages, 1 in 3 adults has prediabetes, causes serious physiological complications, and brings diabetes diagnosis economic difficulties [2–4]. The typical signs of T2DM patients include recurrent urination, increased thirst, exhaustion, increased appetite, and indistinct vision. The main etiology for T2DM is persistent hyperglycemia which provokes mitochondrial dysfunction that stimulates to abundant reactive oxygen species (ROS) formation in several tissues and pancreatic β cells [5, 6]. Such ROS accumulation in pancreatic β cells causes irreparable mitochondrial damage, resulting inhibition of insulin synthesis, and thus leading to diabetes progression by failing to produce enough level of insulin [7, 8]. However, the anti-diabetic drug pathways include stimulating the insulin synthesis, inhibiting the production of endogenous glucose, and blocking carbohydrate absorption from intestine [9, 10]. Currently, six classes of oral antidiabetic drugs, including Metformin, Glimepiride, Repaglinide, Pioglitazone, Sitagliptin, and Acarbose [11] are available which are reported to have serious side effects such as anorexia, nausea, dyspeptic episodes, and diarrhea [12, 13]. Hence, the quest for potential drugs has now become more concentrated. In this regard, a rich source of phytoconstituents with health benefits may be the prospective candidate for T2DM intervention.

For the past few years, a report has shown that wholegrains including sorghum (Sorghum bicolor (L.) Moench) are the potential alternatives to ameliorate T2DM symptoms [14]. Sorghum bicolor (SB) contains a number of secondary metabolites which are reported to be effective in preventing various metabolic diseases, such as cancers, T2DM, obesity, and hyperglycemia [15, 16]. A recent research demonstrated that oral treatment of SB (0.5% and 1%) noticeably reduced the low density lipoprotein cholesterol, triglycerides, and glucose level via PPAR in mice fed a high-fat diet, conversely, expression level of PPAR elevated to 1% [17]. Some reports expound that sorghum extracts at 1.0 mg/ml activates PPAR binding in mouse macrophage cell line; subsequently, PPAR agonists have been emerged as candidates against metabolic dysfunctions with T2DM [18, 19]. Lecka-Czernik B reported that Aleglitazar, being developed by Roche Holding, is a dual agonist for PPARD and PPARA for the promising multiple treatment of hyperglycemia and dyslipidemia with T2DM patients [20]. It is evident that a dual PPAR agonist treatment is more potent than a single agonist treatment. A human study on sub-health condition with prediabetes confirmed that SB administration significantly decreased the level of glucose by 35% [21]. Although literature survey revealed that diabetes and obesity complications can be controlled upon consumption of SB [22, 23]; however, its mechanism(s) against T2DM has not been explored to date. Therefore, the research on bioactive compound(s) and pathways of SB against T2DM should be justified in scientific testing, in order to maintain its pharmacological complements for T2DM.

Network pharmacology is a structured methodical mode, which can investigate the interactive networking elements such as compounds, genes, proteins, and diseases [24, 25]. Network...
pharmacology can decode the mechanism of compounds with a multifunctional point of view, which highlights the interaction of diverse factors, instead of “one target, one compound” [26]. The network pharmacology is therefore a valuable approach to identify potential lead compounds (from natural sources) with specific mechanism of action for the prevention of various diseases, and mostly to elucidate the synergistic impact of bioactive compounds [27]. Zhang B. et al. reported that the rapid development of bioinformatics, systems biology, and poly-pharmacology contributes greatly to network-based drug discovery, which is regarded as a cost-effective drug development method [28]. A report explicates that the network pharmacology is used as a powerful tool to identify the mechanisms of actions between traditional Ge-Gen-Qin-Lian decoction (GGQLD) formula and target genes [29]. In our study, network pharmacology was used to evaluate the bioactive compounds and mechanism(s) of SB against T2DM. Firstly, GC-MS analysis of SB was conducted to identify the bioactive compounds and their “drug-likeness” property was screened by Lipinski’s rule [30]. Secondly, genes related to selected compounds or T2DM were identified using public databases, and overlapping genes between genes related to SB and T2DM target genes were also identified. Thirdly, genes related to a hub signaling were selected by analyzing gene set enrichment analysis. Finally, the selected genes were implemented for molecular docking analysis to find the most potent candidates of SB against T2DM.

2. Materials and methods

2.1 Plant preparation, extraction

The *Sorghum bicolor* (SB) was purchased from Chuncheon local market, Korea. The collected SB was dried and powdered using electric blender. Approximately 500 g of SB powder was soaked in 500 mL of 100% methanol (Daejung, Korea) for 3 days and repeated for 3 times to collect extraction. The solvent extract was collected, filtered, and evaporated using a vacuum evaporator (IKA- RV8, Japan). The evaporated sample was dried under a boiling water bath (IKA-HB10, Japan) at 40°C to obtain yield.

2.2 GC-MS analysis

Agilent 7890A was used to carry out GC-MS analysis. GC was equipped with a DB-5 (30m×0.25mm×0.25μm) capillary column. Initially, the instrument was maintained at a temperature of 100°C for 2.1 minutes. The temperature was risen to 300°C at the rate of 25°C/min and maintained for 20 minutes. Injection port temperature and helium flow rate were ensured as 250°C and 1.5 ml/min, respectively. The ionization voltage was 70 eV. The samples injected in split mode at 5:1. MS scan range was set at 35–550 (m/z). The fragmentation patterns of mass spectra were compared with those stored in the using W8N05ST Library MS database. The percentage of each compound was calculated from the relative peak area of each compound in the chromatogram. The concept of integration used the ChemStation integrater algorithms.

2.3 Chemical compounds database construction, drug-likeness, and oral bioavailability filtering

The information of chemical compounds from SB was identified by utilizing GC-MS analysis which were filtered according to the Lipinski’s rule through SwissADME (http://www.swissadme.ch/) to identify “Drug-likeness” property and oral bioavailability score. The PubChem (https://pubchem.ncbi.nlm.nih.gov/) was utilized for identification of the SMILES (Simplified Molecular Input Line Entry System) of compounds.
2.4 Target genes related to selected compounds or T2DM

Based on the SMILES, target genes linked to the compounds were selected through both Similarity Ensemble Approach (SEA) (http://sea.bkslab.org/) and Swiss Target Prediction (STP) (http://www.swisstargetprediction.ch/) with "Homo Sapiens" mode. T2DM related genes were identified by DisGeNET (https://www.disgenet.org/search) and OMIM (https://www.ncbi.nlm.nih.gov/omim) databases. The overlapping genes between compounds of SB and T2DM target genes were identified and visualized by VENNY 2.1 (https://bioinfogp.cnb.csic.es/tools/venny/).

2.5 Network construction of interacted overlapping genes

Through STRING (https://string-db.org/) analysis, the overlapping genes were closely correlated, and the signaling pathways of overlapping genes were analyzed by RStudio bubble chart. Networking between bioactive compounds and genes of SB against T2DM identified a hub signaling pathway.

2.6 Preparation for molecular docking of ligand molecules

The ligand molecules were converted.sdf from PubChem into.pdb format using Pymol, and the ligand molecules were converted into.pdbqt format through Autodock.

2.7 Preparation for molecular docking of target proteins

Six target proteins of T2DM i.e. FABP3 (PDB ID: 5HZ9), FABP4 (PDB ID: 3P6D), NR1H3 (PDB ID: 2ACL), PPARA (PDB ID: ASP6), PPARD (PDB ID: 5U3Q), PPARG (PDB ID: 3E00) were selected on STRING via RCSB PDB (https://www.rcsb.org/). The proteins selected as PDB format converted into.pdbqt format via Autodock (http://autodock.scripps.edu/).

2.8 Ligand- protein docking

The ligand molecules were docked with target proteins utilizing autodock4 by setting-up 4 energy range and 8 exhaustiveness as default to obtain 10 different poses of ligand molecules [31]. The 2D binding interactions was identified through LigPlot+ v.2.2 (https://www.ebi.ac.uk/thornton-srv/software/LigPlus/). After docking, ligands of lowest binding energy were selected to visualize the ligand-protein interaction in Pymol.

3. Results

3.1 Potential bioactive compounds from SB

A total of 20 compounds in SB were detected by the GC-MS analysis (Fig 1), and the name of compounds, retention time, peak area (%) are enlisted in Table 1. All 20 compounds were checked and accepted by Lipinski’s rule (Molecular Weight ≤ 500g/mol; Moriguchi octanol-water partition coefficient ≤4.15; Number of Nitrogen or Oxygen ≤10; Number of NH or OH ≤5), and all compounds have satisfactory “Abbott Bioavailability Score (> 0.1)” identified through SwissADME (Table 2).

3.2 Overlapping genes between SEA and STP linked to 20 compounds

Based on the SMILES, a total of 308 genes from SEA and 324 genes from STP linked to 20 compounds were extracted (S1 Table). The result of Venn diagram exhibited that 118 genes were overlapped between the two public databases (Fig 2).
Fig 1. A typical GC-MS chromatogram of the chemical compounds of the methanol extract of SB with indication of 4 main chemical constituents.

https://doi.org/10.1371/journal.pone.0240873.g001

Table 1. A list of the identified 20 chemical compounds from SB through GC-MS.

| No. | Compound                                      | Pubchem ID | Retention time | Area (%) |
|-----|-----------------------------------------------|------------|----------------|----------|
| 1   | Glycerin                                      | 753        | 3.606          | 2.34     |
| 2   | Glyceraldehyde                                | 751        | 4.222          | 0.19     |
| 3   | 2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-2-one | 67452387   | 4.76           | 0.35     |
| 4   | β-D-ribofuranosyl-cytosine                    | 596        | 7.039          | 3.25     |
| 5   | Butanoic acid, ethyl ester                    | 7762       | 7.318          | 0.11     |
| 6   | 2-Propanol, 1-chloro-3-(1-methylethoxy)        | 94290      | 7.847          | 0.84     |
| 7   | Oxazole, 5-hexyl-2,4-dimethyl-                | 573458     | 8.222          | 0.15     |
| 8   | Hexadecanoic acid, methyl ester               | 8181       | 8.76           | 0.24     |
| 9   | Palmitic acid                                 | 985        | 8.991, 9.270, 9.308 | 13.67 |
| 10  | Methyl linoleate                              | 5284421    | 9.424          | 2.38     |
| 11  | Linoleic acid                                 | 5280450    | 10.106, 10.414, 10.943 | 68.2 |
| 12  | 2-Stearoylglycerol                            | 79075      | 10.943         | 0.72     |
| 13  | Propylene glycol monololate                   | 5365625    | 11.741         | 3.02     |
| 14  | 25-Oxo-27-norcholesterol                      | 165617     | 11.837         | 0.95     |
| 15  | Cholesterol                                   | 5997       | 12.279         | 0.14     |
| 16  | 5,8-Dimethyltocol                             | 86052      | 14.01          | 0.26     |
| 17  | Campesterol                                   | 173183     | 16.058         | 0.77     |
| 18  | Stigmasterol                                  | 5280794    | 16.356         | 0.42     |
| 19  | β-sitosterol                                   | 222284     | 17.164         | 1.52     |
| 20  | 4,5-Dihydroxycoumarin                         | 54690194   | 19.991         | 0.28     |

https://doi.org/10.1371/journal.pone.0240873.t001
Overlapping genes between T2DM-related genes and the 118 overlapping genes

A total of 4,736 genes related to T2DM were sorted by retrieving DisGeNET and OMIM databases (S2 Table). The result of Venn diagram unveiled that 81 overlapping genes was identified between 4,763 genes related to T2DM and the 118 overlapping genes (Fig 3), (S3 Table). As shown in S4 Table, a total of 81 overlapping genes linked to 16 compounds from aforementioned 20 compounds were identified, retrieving from both SEA and STP public databases, and no genes were found associated with other 4 compounds (Glycerin; Glyceraldehyde; 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-2-one; and 2-propanol, 1-chloro-3-(1-methylethoxy)) in the two databases.

Gene-gene network analysis of 16 compounds of SB against T2DM

The final overlapping 81 genes were closely linked to each other with 81 nodes and 347 edges (Fig 4). The interaction between 16 compounds and 81 genes resulted with 97 nodes and 347 edges (Fig 5), which indicated that the therapeutic efficacy of SB on T2DM. The 16 compounds were classified as five steroid derivatives (25-Oxo-27-norcholesterol, Cholesterol, Campesterol, (E)-23-ethylcholesta-5,22-dien-3β-ol, and β-sitosterol), four fatty acyls (Palmitic acid, Methyl linoleate, Linoleic acid, and Propyleneglycol monoleate), two fatty acid esters (Butanoic acid-ethyl ester and Hexadecanoic acid-ethyl ester), one organooxygen (Propanal, Table 2. Physicochemical properties of the 20 compounds for good oral bioavailability.

| No. | Compounds                        | Lipinski Rules | Lipinski's Violations | Biavailability Score |
|-----|----------------------------------|----------------|-----------------------|---------------------|
|     |                                  | MW (g/mol)     | HBA                  | HBD                 | MLog P       | ≤ 5 | ≤ 1.5 | ≤ 1 | > 0.1 |
| 1   | Glycerin                         | 92.09          | 3                    | 3                   | -1.51        | 0   | 0     | 0.55 |
| 2   | Propanol, 2,3-dihydroxy-         | 90.08          | 3                    | 2                   | -1.66        | 0   | 0     | 0.55 |
| 3   | 2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-2-one | 144.13 | 4 | 2 | -0.96 | 0 | 0.55 |
| 4   | β-D-ribofuranosyl-cytosine       | 243.22         | 6                    | 5                   | -2.29        | 0   | 0.55 |
| 5   | Butanoic acid, ethyl ester       | 116.16         | 2                    | 0                   | 1.27         | 0   | 0.55 |
| 6   | 2-Propanol, 1-chloro-3-(1-methylethoxy) | 152.62 | 2 | 1 | 0.96 | 0 | 0.55 |
| 7   | Oxazole, 5-hexyl-2,4-dimethyl-    | 181.27         | 2                    | 0                   | 1.92         | 0   | 0.55 |
| 8   | Hexadecanoic acid, methyl ester  | 270.45         | 2                    | 0                   | 4.44         | 1   | 0.55 |
| 9   | Palmitic acid                    | 256.42         | 2                    | 1                   | 4.19         | 1   | 0.85 |
| 10  | Methyl linoleate                 | 294.47         | 2                    | 0                   | 4.70         | 1   | 0.55 |
| 11  | Linoleic acid                    | 280.45         | 2                    | 1                   | 4.47         | 1   | 0.85 |
| 12  | 2-Stearyl glycerol               | 358.56         | 4                    | 2                   | 3.63         | 0   | 0.55 |
| 13  | Propylenglycol monoleate         | 340.54         | 3                    | 1                   | 4.37         | 1   | 0.55 |
| 14  | 25-Oxo-27-norcholesterol         | 386.61         | 2                    | 1                   | 5.1          | 1   | 0.55 |
| 15  | Epicholesterol                   | 386.65         | 1                    | 1                   | 6.34         | 1   | 0.55 |
| 16  | 3,8-Dimethyltocol                | 416.68         | 2                    | 1                   | 5.94         | 1   | 0.55 |
| 17  | Campesterol                      | 400.68         | 1                    | 1                   | 6.54         | 1   | 0.55 |
| 18  | (E)-23-ethylcholesta-5,22-dien-3β-ol | 412.69 | 1 | 1 | 6.62 | 1 | 0.55 |
| 19  | β-sitosterol                     | 414.71         | 1                    | 1                   | 6.73         | 1   | 0.55 |
| 20  | 4,5-Hydroxycoumarin              | 178.14         | 3                    | 1                   | 1.04         | 0   | 0.55 |

MW, Molecular Weight (g/mol); HBA, Hydrogen Bond Acceptor; HBD, Hydrogen Bond Donor; LogP, Lipophilicity; Bioavailability Score, the ability of a drug or other substance to be absorbed and used by the body.

https://doi.org/10.1371/journal.pone.0240873.t002

3.3 Overlapping genes between T2DM-related genes and the 118 overlapping genes

A total of 4,736 genes related to T2DM were sorted by retrieving DisGeNET and OMIM databases (S2 Table). The result of Venn diagram unveiled that 81 overlapping genes was identified between 4,763 genes related to T2DM and the 118 overlapping genes (Fig 3), (S3 Table). As shown in S4 Table, a total of 81 overlapping genes linked to 16 compounds from aforementioned 20 compounds were identified, retrieving from both SEA and STP public databases, and no genes were found associated with other 4 compounds (Glycerin; Glyceraldehyde; 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-2-one; and 2-propanol, 1-chloro-3-(1-methylethoxy)) in the two databases.

3.4 Gene-gene network analysis of 16 compounds of SB against T2DM

The final overlapping 81 genes were closely linked to each other with 81 nodes and 347 edges (Fig 4). The interaction between 16 compounds and 81 genes resulted with 97 nodes and 347 edges (Fig 5), which indicated that the therapeutic efficacy of SB on T2DM. The 16 compounds were classified as five steroid derivatives (25-Oxo-27-norcholesterol, Cholesterol, Campesterol, (E)-23-ethylcholesta-5,22-dien-3β-ol, and β-sitosterol), four fatty acyls (Palmitic acid, Methyl linoleate, Linoleic acid, and Propylenglycol monoleate), two fatty acid esters (Butanoic acid-ethyl ester and Hexadecanoic acid-ethyl ester), one organooxygen (Propanal,
2,3-dihydroxy-), one prenol lipid (5,8-Dimethyltocol), one pyrimidine nucleoside (β-D-ribofuranosyl-cytosine), one azole (Oxazole, 5-hexyl-2,4-dimethyl), and one coumarin derivative (4,5-Dihydroxycoumarin).

3.5 Signaling pathways and finding of a hub signaling of SB against T2DM

The result of KEGG pathway enrichment analysis demonstrated that 81 genes were related to 12 signaling pathways (False Discovery Rate < 0.05). The 12 signaling pathways were directly related to the progression of T2DM and indicated that these 12 signaling pathways might be the key pathways of SB against T2DM. The description of 12 signaling pathways is shown in Table 3. Additionally, a bubble chart suggested that PPAR signaling pathway might be a hub signaling pathway of SB against T2DM (Fig 6).

3.6 Molecular docking investigation of 6 genes and 4 compounds related to PPAR signaling pathway

From the SEA and STP databases, it was revealed that FABP3 gene is associated with six compounds (Methyl lineoleate, Linoleic acid, Hexadecanoic acid-methyl ester, Palmitic acid, Propyleneglycol monoleate, and 25-Oxo-27-norcholesterol), FABP4 gene is related to six compounds (Methyl lineoleate, Linoleic acid, Hexadecanoic acid-methyl ester, Palmitic acid, Propyleneglycol monoleate, and 25-Oxo-27-norcholesterol), NR1H3 gene is involved with 8
compounds (β-sitosterol, Campesterol, 25-Oxo-27-norcholesterol, Cholesterol, Methyl linoleate, 5,8-Dimethyltocotoc, Linoleic acid, and Stigmasterol), PPARA gene is related to 7 compounds (Palmitic acid, Hexadecanoic acid-methyl ester, Linoleic acid, Methyl linoleate, Propyleneglycol monoleate, β-sitosterol, and 25-Oxo-27-norcholesterol), PPARD gene is associated with 8 compounds (Hexadecanoic acid-methyl ester, Linoleic acid, Methyl linoleate, Stigmasterol, 25-Oxo-27-norcholesterol, Palmitic acid, Cholesterol, and β-sitosterol), PPARG gene is linked to 7 compounds (Methyl linoleate, Linoleic acid, Palmitic acid, Propyleneglycol monoleate, β-sitosterol, Hexadecanoic acid-methyl ester, and 25-Oxo-27-norcholesterol) (Fig 7). Also, each six proteins have strong molecular interactions on PPAR signaling pathway (Fig 8). The nominated compounds to dock with six proteins were selected via both SEA and STP.

The molecular docking analysis was performed to evaluate the binding energy of these six genes against their related each gene, respectively, and the docking figures are depicted in Fig 9. Molecular docking score of A1-A6 on FABP3 protein (PDB ID: 5HZ9) is analyzed in the “Homo Sapiens” mode. Docking simulation of the affinity between A1-A6 and FABP3 protein in the “Homo sapiens” setting was analyzed. Based on the docking score, the order of the priority of binding energy is given: A5 > A6 > A2 > A3 > A1 > A4. The six-binding energy of A1-FABP3, A2-FABP3, A3-FABP3, A4-FABP3, A5-FABP3, and A6-FABP3 demonstrated -6.6, -7.4, -6.7, -6.5, -8.4, and -7.8 kcal/mol, respectively. Interaction analysis of the best-docked compound namely “propyleneglycol monoleate” showed several hydrophobic bonds on FABP3.
protein (PDB ID: 5HZ9). The hydrophobic amino acid residues are Thr-57, Phe-58, Val-33, Met-36, Gly-27, Gly-25, Phe-28, and Gln-32. The detailed information is enlisted in Table 4. The Propylene glycol monol eate (A5) had the strongest affinity on FABP3. Docking simulation of the affinity between B1-B6 and FABP4 protein (PDB ID: 3P6D) in the "Homo sapiens" setting revealed promising binding affinity, and the order of the priority of binding energy is as follows: B6>B5>B2>B1>B3>B4. The six-binding energy of B1-FABP4, B2-FABP4, B3-FABP4, B4-FABP4, B5-FABP4, and B6-FABP4 revealed -4.6, -4.9, -4.5, -4.4, -5.6, and -7.2 kcal/mol, respectively. The 25-Oxo-27-norcholesterol (B6) had the strongest affinity on FABP4. Interaction analysis of best-docked compound namely “25-Oxo-27-norcholesterol” resulted one
Fig 5. The interaction between 16 compounds and 81 genes (94 nodes and 356 edges) on T2DM.

Table 3. Target genes in 12 signaling pathways enrichment related to T2DM.

| KEGG ID                                                                 | Target genes                                                                 | False Discovery Rate |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------|
| hsa04933:AGE-RAGE signaling pathway in diabetic complications            | AKT1,NFKB1,PRKCA,PRKCE                                                      | 0.0075               |
| hsa04920:Adipocytokine signaling pathway                                 | AKT1,PPARA,NFKB1                                                            | 0.0208               |
| hsa04917:Prolactin signaling pathway                                     | ESR1,ESR2,AKT1,NFKB1,CYP17A1                                                | 0.00031              |
| hsa04915:Estrogen signaling pathway                                      | AKT1,GABBR1,ESR1,PGR,ESR2                                                   | 0.0028               |
| hsa04664:Fcepsilon RI signaling pathway                                 | AKT1,ALOX5,PLA2G4A,PRKCA                                                   | 0.0021               |
| hsa04660:T cell receptor signaling pathway                              | AKT1,NFKB1,PTPRC                                                            | 0.0408               |
| hsa04370:VEGF signaling pathway                                         | AKT1,PRKCA,PLA2G4A                                                         | 0.0155               |
| hsa04152:AMPK signaling pathway                                         | AKT1,HNF4A,PPARG,HMGCR                                                     | 0.013                |
| hsa04071:Sphingolipid signaling pathway                                 | ADORA1,S1PR1,AKT1,NFKB1,PRKCA                                               | 0.00029              |
| hsa04021:cAMP signaling pathway                                         | ADORA1,GABBR1,AKT1,PTGER3,PPARA,NFKB1                                       | 0.0022               |
| hsa03320:PPAR signaling pathway                                         | FABP3,FABP4,NR1H3,PPARA,PPARD,PPARG                                         | 0.0000419            |
| hsa04066:HIF-1 signaling pathway                                         | GAPDH,AKT1,NFKB1,PRKCA                                                     | 0.0075               |
hydrogen bond (Ser-1) and seven hydrophobic bonds (Gly-88, Leu-86, Met-0, Val-44, Cys-1, Gly-46, and ASP-47). The detailed information is enlisted in Table 5. Docking simulation of the affinity between C1-C8 and NR1H3 protein in the "Homo sapiens" setting displayed promising binding affinity, and the order of the priority of binding energy is as follows: 

C2>C8>C3>C4>C1>C7>C6>C4. The eight-binding energy of C1-NR1H3, C2-NR1H3, C3-NR1H3, C4-NR1H3, C5-NR1H3, C6-NR1H3, C7-NR1H3, and C8-NR1H3 exhibited -7.3, -10.6, -7.9, -7.6, -4.9, -5.7, -5.9, and -8.3 kcal/mol, respectively. The campesterol (C2) has the strongest affinity on NR1H3. Interaction analysis of best-docked compound namely "campesterol" showed several hydrophobic bonds on NR1H3 protein (PDB ID: 2ACL). The hydrophobic amino acid residues are Gly-328, Arg-248, Leu-329, Gln-330, Val-331, Ile-299, Arg-302, Val-298, Asp-295, Leu-294, and Gln-429. The detailed information is enlisted in Table 6. Docking simulation of the affinity between D1-D8 and PPARA protein in the "Homo sapiens" setting revealed promising binding affinity, and the order of the priority of binding energy is as follows: 

D6>D7>D3>D5>D2>D1>D4. The eight-binding energy of D1-PPARA, D2-PPARA, D3-PPARA, D4-PPARA, D5-PPARA, D6-PPARA, and D7-PPARA exhibited -4.9, -5.2, -6.0, -4.8, -5.8, -6.6, and -6.1 kcal/mol, respectively. The β-sitosterol (D6) has the strongest affinity on NR1H3. Interaction analysis of best-docked compound namely "β-sitosterol" displayed several hydrophobic bonds on PPARA protein (PDB ID: 3SP6). The hydrophobic amino acid residues are Glu-462, Ser-588, Leu-392, Asn-303, Val-306, Thr-307, Lys-310, Tyr-311, Gly-390, Pro-389, Arg-465, and Asp-466. The detailed information is enlisted in Table 7. Docking simulation of the affinity between E1-E8 and PPARD protein in the "Homo sapiens" setting displayed promising binding affinity, and the order of the priority of binding energy is as follows: 

The eight-binding energy of E1-PPARD, E2-PPARD, E3-PPARD, E4-PPARD, E5-PPARD, E6-PPARD, E7-PPARD, and E8-PPARD exhibited -3.8, -5.2, -4.2, -7.3, -7.3, -4.6, -7.3, and -7.4 kcal/mol.
kcal/mol, respectively. The β-sitosterol (E8) has the strongest affinity on PPARD. Interaction analysis of best-docked compound namely “β-sitosterol” revealed one hydrogen bond (Met-440) and seven hydrophobic bonds (Ala-414, Thr-411, Tyr-441, Asp-360, Pro-362, Tyr-284, and Val-410). The detailed information is enlisted in Table 8. Docking simulation of the affinity between E1-E8 and PPARD protein in the “Homo sapiens” setting displayed promising binding affinity, and the order of the priority of binding energy is as follows: The seven-binding energy of F1-PPARG, F2-PPARG, F3-PPARG, F4-PPARG, F5-PPARG, F6-PPARG, and F7-PPARG exhibited -5.2, -5.4, -5.2, -5.9, -7.9, -4.0, and -7.8 kcal/mol, respectively. Interaction analysis of best- docked compound namely “β-sitosterol” exposed several hydrophobic bonds on PPARG protein (PDB ID: 3E00). The hydrophobic amino acid residues are Tyr-169, Tyr-189, Leu-167, Thr-168, Lys-336, Arg-350, Glu-351, Lys-354, Gln-193, and Tyr-192. The β-sitosterol (F5) has the strongest affinity on PPARG. The detailed information is enlisted in Table 9. This result suggested that each compound of the highest affinity score on each gene might be significant ligand to control glucose homeostasis (Fig 10).
4. Discussion

Compounds-genes networking system unveiled that therapeutic effect of SB against T2DM was related to 16 compounds out of 20 compounds detected by GC-MS, including five steroid derivatives, four fatty acyls, two fatty acid esters, one organooxygen, one prenol lipid, one pyrimidine nucleoside, one azole, and one coumarin. The proportion of steroid derivatives to 16 compounds was close to 30%, implying that steroid derivatives was the most essential than any other sorts of compounds for the amelioration effect of SB on T2DM.

It was reported that some steroid derivatives have strong effect on hypoglycemic activity based on lipophilic properties [32]. Noticeably, a report showed that β-sitosterol (steroid derivatives) controls the glycemic level through regulation of IR (insulin receptor) and GLUT4 (glucose transporter 4) proteins in adipocytes of high fat and sucrose treated type 2 diabetic rats, interestingly, the in vivo result was in line with in silico analysis [33]. In addition, researchers found that campesterol (steroid derivatives) decreases the LDL (Low Density Lipoprotein) level, associated with the occurrence and development of T2DM [34, 35]. A patent revealed that propyleneglycol monoleate is an agent for treatment or amelioration of diabetes, obesity or arteriosclerosis [36]. Another report suggested that 25-Oxo-27-norcholesterol interrupts cholesterol oxidation, which is related to insulin resistance [37, 38]. These results coincide
with our findings of SB on T2DM, suggesting that the quantity of the four compounds in SB is greatly enough to exhibit anti-diabetic efficacy.

Compounds-genes networking also specified that the pharmacological effect of SB on T2DM was directly associated with 81 genes. The results of KEGG pathway enrichment analysis of 81 genes showed that 12 signaling pathways were directly linked to the occurrence and progression of T2DM, demonstrating that these signaling pathways might be the key pathways of SB against T2DM. The 12 signaling pathways with T2DM were succinctly discussed as follows.

PPAR signaling pathway: PPAR ligands are the potential therapeutic candidates against T2DM, also, alleviate metabolic syndrome including obesity and insulin resistance [39]. Furthermore, dual agonists approach with both PPARA agonists (such as fibrates) and PPARG agonists (such as thiazolidinediones) can have better metabolic efficacy and less side effects than its single administration [40]. cAMP signaling pathway: cAMP signaling pathway modulates glucose homeostasis with insulin and glucagon secretion, glucose uptake, gluconeogenesis, glycogen synthesis and breakdown of glucose [41]. HIF-1 signaling pathway: Inhibition of HIF-1 signaling caused by diabetes is associated with hypoxia and high degradation of HIF-1α.
### Table 4. Binding energy and interactions of potential active compounds on FABP3 (PDB ID: 5HZ9).

| Protein | Ligand                  | PubChem ID | Symbol | Binding energy (kcal/mol) | Hydrogen Bond Interactions | Hydrophobic Interactions |
|---------|-------------------------|------------|--------|---------------------------|----------------------------|--------------------------|
| 5HZ9    | Methyl lineoleate       | 5284421    | A1     | -6.6                      | n/a                        | Phe-58, Lys-22, Gly-25, Phe-28, Gln-32, Ala-29 |
|         | Linoleic acid           | 5280450    | A2     | -7.4                      | Lys-22                     | Ala-29, Gln-32, Phe-28, Gly-25, Gly-27 |
|         | Hexadecanoic acid, methyl ester | 8181 | A3     | -6.7                      | n/a                        | Phe-58, Ala-29, Lys-22 |
|         | Palmitic acid           | 985        | A4     | -6.5                      | n/a                        | Val-33, Gln-32, Ala-29, Phe-58, Lys-22, Thr-57 |
|         | Propylene glycol monoleate | 5365625   | A5     | -8.4                      | n/a                        | Thr-57, Phe-58, Val-33, Met-36, Gly-27, Gly-25, Phe-28, Gln-32 |
|         | 25-Oxo-27-norcholesterol | 165617     | A6     | -7.8                      | Ser-35, Met-36             | Asp-18, Phe-28, Ala-29, Val-33, Asp-99, Gln-32, Lys-10 |

https://doi.org/10.1371/journal.pone.0240873.t004

### Table 5. Binding energy and interactions of potential active compounds on FABP4 (PDB ID: 3P6D).

| Protein | Ligand                  | PubChem ID | Symbol | Binding energy (kcal/mol) | Hydrogen Bond Interactions | Hydrophobic Interactions |
|---------|-------------------------|------------|--------|---------------------------|----------------------------|--------------------------|
| 3P6D    | Methyl linoleate        | 5284421    | B1     | -4.6                      | n/a                        | Ser-1, Cys-1, Leu-66, Asp-47, Leu-66, Ile-49 |
|         | Linoleic acid           | 5280450    | B2     | -4.9                      | Leu-86                     | Thr-85, Leu-66, Asp-47, Cys-1 |
|         | Hexadecanoic acid, methyl ester | 8181 | B3     | -4.4                      | n/a                        | Gly-88, Leu-86, Ser-1, Gly-46, Asp-47, Leu-66, Met-0 |
|         | Palmitic acid           | 985        | B4     | -4.4                      | Glu-72, Val-80             | Lys-79, Asp-71, Val-73, Glu-61, Thr-60 |
|         | Propylene glycol monoleate | 5365625   | B5     | -5.6                      | Gly-88, Leu-86             | Asp-87, Met-0, Ser-1, Cys-1, Asp-47, Leu-66, Ile-65 |
|         | 25-Oxo-27-norcholesterol | 165617     | B6     | -7.2                      | Ser-1                      | Gly-88, Leu-86, Met-0, Val-44, Cys-1, Gly-46, Asp-47 |

https://doi.org/10.1371/journal.pone.0240873.t005
protein [42]. Sphingolipid signaling pathway: Sphingolipid is a significant class of signaling lipids, have been recognized as vital players in the progression and pathogenesis of insulin resistance and T2DM [43]. AMPK signaling pathway: The activation of AMPK enhances homeostasis of glycemic level, lipid concentration, and blood pressure in insulin-resistant

### Table 6. Binding energy and interactions of potential active compounds on NR1H3 (PDB ID: 2ACL).

| Protein  | Ligand          | PubChem ID | Symbol | Binding energy (kcal/mol) | Hydrogen Bond Interactions | Hydrophobic Interactions |
|----------|-----------------|------------|--------|--------------------------|---------------------------|--------------------------|
| 2ACL     | β-sitosterol    | 222284     | C1     | -7.3                     | n/a                       | His-395, Pro-396         |
|          |                 |            |        |                          |                           | His-397, Gln-243         |
|          |                 |            |        |                          |                           | Pro-242, Asp-398         |
|          |                 |            |        |                          |                           | Ser-244, Gln-346         |
|          |                 |            |        |                          |                           | Asp-241, Gln-348         |
|          |                 |            |        |                          |                           | Asn-394                  |
| Campesterol | 173183         | C2         |        | -10.6                    | n/a                       | Gly-328, Arg-248         |
|          |                 |            |        |                          |                           | Leu-329, Gln-330         |
|          |                 |            |        |                          |                           | Val-331, Ile-299         |
|          |                 |            |        |                          |                           | Arg-302, Val-298         |
|          |                 |            |        |                          |                           | Asp-295, Leu-294         |
|          |                 |            |        |                          |                           | Gln-429                  |
| 25-Oxo-27-norcholesterol | 165617 | C3 |        | -7.9                     | Glu-339, Arg-404          | Asp-379, Glu-390         |
|          |                 |            |        |                          |                           | Ala-343, Asp-241         |
|          |                 |            |        |                          |                           | Pro-242, Leu-347         |
|          |                 |            |        |                          |                           | Pro-240, Glu-346         |
|          |                 |            |        |                          |                           | Pro-386                  |
| Cholesterol | 5997            | C4         |        | -7.6                     | Asn-385                  | Trp-236, Ala-391         |
|          |                 |            |        |                          |                           | Pro-237, Ile-238         |
|          |                 |            |        |                          |                           | Glu-394, Pro-242         |
|          |                 |            |        |                          |                           | Asp-241, Pro-240         |
|          |                 |            |        |                          |                           | Glu-322, Lys-395         |
|          |                 |            |        |                          |                           | Lys-326, Glu-388         |
| Methyl linoleate | 5284421 | C5 |        | -4.9                     | Arg-342                  | Ile-238, Pro-378         |
|          |                 |            |        |                          |                           | Ala-387, Pro-386         |
|          |                 |            |        |                          |                           | Glu-390, Ser-411         |
|          |                 |            |        |                          |                           | Phe-340, Asp-379         |
|          |                 |            |        |                          |                           | Glu-339                  |
| 5,8-Dimethyltocol | 222284 | C6 |        | -5.7                     | n/a                      | Leu-347, Pro-242         |
|          |                 |            |        |                          |                           | Ser-244, Asp-241         |
|          |                 |            |        |                          |                           | Glu-291, Gln-348         |
|          |                 |            |        |                          |                           | Gln-243, Glu-346         |
|          |                 |            |        |                          |                           | His-397, Asp-398         |
|          |                 |            |        |                          |                           | Met-401                  |
| Linoleic acid | 5280450 | C7 |        | -5.9                     | Gly-328, Gln-422          | Leu-329, Gln-330         |
|          |                 |            |        |                          |                           | Gln-429, Asp-295         |
|          |                 |            |        |                          |                           | Val-331, Lys-381         |
|          |                 |            |        |                          |                           | Ile-299, Ala-303         |
|          |                 |            |        |                          |                           | Arg-302, Glu-332         |
|          |                 |            |        |                          |                           | Gly-382, Ala-425         |
|          |                 |            |        |                          |                           | Val-298                  |

https://doi.org/10.1371/journal.pone.0240873.t006
rodents, which is considered as an important therapeutic target against T2DM [44]. VEGF signaling pathway: VEGF is related deeply to the development of T2DM. High content of VEGF is generally detected in plasma of T2DM patients [45]. T cell receptor activation: Overactivated T cells with T2DM patients might be an indication of losing the natural regulatory mechanism,

| Protein | Ligand | PubChem ID | Symbol | Binding energy (kcal/mol) | Amino Acid Residue | Amino Acid Residue |
|---------|--------|------------|--------|---------------------------|-------------------|-------------------|
| 3SP6    | Palmitic acid | 985 | D1 | -4.9 | n/a | Glu-251, Val-332 |
|         |         |         |       |                | Ile-241, Ala-333  |
|         |         |         |       |                | Thr-279, Val-255  |
|         |         |         |       |                | Tyr-334, Leu-258  |
|         |         |         |       |                | Cys-275           |
|         | Hexadecanoic acid, methyl ester | 8181 | D2 | -5.2 | n/a | Ile-317, Ser-323 |
|         |         |         |       |                | Phe-218, Met-220  |
|         |         |         |       |                | Asn-221, Val-324  |
|         |         |         |       |                | Asn-219, Tyr-334  |
|         |         |         |       |                | Ala-333, Thr-279  |
|         |         |         |       |                | Leu-331, Thr-283  |
|         | Linoleic acid | 5280450 | D3 | -6 | Ser-323 | Asn-221, Met-320 |
|         |         |         |       |                | Tyr-214           |
|         | Methyl linoleate | 5284421 | D4 | -4.8 | n/a | Glu-286, Asn-219 |
|         |         |         |       |                | Gly-335, Tyr-334  |
|         |         |         |       |                | Thr-279, Val-324  |
|         |         |         |       |                | Leu-331, Thr-283  |
|         |         |         |       |                | Met-220, Phe-218  |
|         | Propyleneglycol monoleate | 5365625 | D5 | -5.8 | n/a | Glu-251, Ala-250 |
|         |         |         |       |                | Val-255, Ala-333  |
|         |         |         |       |                | Met-220, Val-324  |
|         |         |         |       |                | Thr-279, Tyr-334  |
|         |         |         |       |                | Leu-54 |
|         | β-sitosterol | 222284 | D6 | -6.6 | n/a | Glu-462, Ser-688 |
|         |         |         |       |                | Leu-392, Asn-303  |
|         |         |         |       |                | Val-306, Thr-307  |
|         |         |         |       |                | Lys-310, Tyr-311  |
|         |         |         |       |                | Gly-390, Pro-389  |
|         |         |         |       |                | Arg-465, Asp-466  |
|         | 25-Oxo-27-norcholesterol | 165617 | D7 | -6.1 | Lys-345 | Asp-360, Glu-356 |
|         |         |         |       |                | Pro-357, Glu-439  |
|         |         |         |       |                | His-440, Leu-443  |
|         |         |         |       |                | Asp-353           |

https://doi.org/10.1371/journal.pone.0240873.t007
intervention of T cells by T2DM might down T cell receptor sensitization [46]. Fc epsilon RI signaling pathway: Fc epsilon RI- mediated signaling in mouse bone marrow is potentiated by insulin [47]. Estrogen signaling pathway: In a research of postmenopausal mice and human cells, the report demonstrated that estrogen is related to lower risk of T2DM by targeting particular cells in the pancreas and gut to improve tolerance to glucose [48]. Prolactin signaling pathway: A normal range of prolactin concentration is linked to a lower T2DM risk, which may play an inhibitory effect on the development of T2DM [49]. Adipocytokine signaling pathway: Adipocytokines leptin and adiponectin might be significant biomarkers for first prediction on T2DM, which is further associated with diabetic microvascular complications [50].

Table 8. Binding energy and interactions of potential active compounds on PPARD (PDB ID: 5U3Q).

| Protein       | Ligand                          | PubChem ID | Symbol | Binding energy (kcal/mol) | Hydrogen Bond Interactions | Hydrophobic Interactions |
|---------------|---------------------------------|------------|--------|--------------------------|----------------------------|--------------------------|
| 5U3Q          | Hexadecanoic acid, methyl ester | 8181       | E1     | -3.8                     | Pro-362, Tyr-284           | Arg-407, Glu-288         |
|               |                                 |            |        |                          |                            | Arg-361, Met-440          |
|               |                                 |            |        |                          |                            | Val-410, Thr-411          |
| Linoleic acid | 5280450                         | E2         |        | -5.2                     | Val-410, Arg-407           | Met-440, Asp-439          |
|               |                                 |            |        |                          |                            | Thr-411, Tyr-441          |
| Methyl linoleate | 5284421                        | E3         |        | -4.2                     | Val-410                   | Arg-407, Glu288           |
|               |                                 |            |        |                          |                            | Tyr-284, Pro-362          |
|               |                                 |            |        |                          |                            | Met-440, Thr-411          |
| Stigmasterol  | 5280794                         | E4         |        | -7.3                     | Ala-414, Thr-411           | Tyr-441, Asp-360          |
| 25-Oxo-27-norcholesterol | 165617  | E5       |        | -7.3                     | Ala-414, Thr-411           | Pro-362, Tyr-284          |
| Palmitic acid | 985                             | E6         |        | -4.6                     | Val-410                   | Tyr-441, Pro-362          |
|               |                                 |            |        |                          |                            | Arg-361, Val-410          |
|               |                                 |            |        |                          |                            | Tyr-284, Glu-288          |
| Cholesterol   | 5997                            | E7         |        | -7.3                     | Val-410, Ala-414           | Asp-360, Arg-361          |
|               |                                 |            |        |                          |                            | Pro-362, Thr-411          |
| β-sitosterol  | 222284                          | E8         |        | -7.4                     | Ala-414, Thr-411           | Tyr-441, Asp-360          |
|               |                                 |            |        |                          |                            | Pro-362, Tyr-284          |

https://doi.org/10.1371/journal.pone.0240873.t008
AGE-RAGE signaling pathway in diabetic complications: The activation of receptor for AGE (RAGE) is a noticeable pathological consequence on T2DM, and thus the design of antagonist for the AGE(RAGE) receptor might be a therapeutic strategy against T2DM [51].

Collectively, this study suggests that 12 signaling pathways with 81 genes are linked to the development of T2DM. In addition, rich factor defines that the proportion of the DEGs number and the number of genes have been annotated in pathway [52]. In other words, the higher of the rich factor is, the higher the degree of enrichment. The rich factor of PPAR signaling

| Protein | Ligand | PubChem ID | Symbol | Binding energy (kcal/mol) | Hydrogen Bond Interactions | Hydrophobic Interactions |
|---------|--------|------------|--------|--------------------------|---------------------------|--------------------------|
| 3E00    | Methyl linolate | 5284421 | F1     | -5.2                     | Tyr-169, Gln-193          | Leu-167, Asp-337          |
|         |        |           |        |                          | Lys-336, Val-372          |                          |
|         |        |           |        |                          | Lys-373, Glu-369          |                          |
|         |        |           |        |                          | Tyr-189, Thr-168          |                          |
|         |        |           |        |                          | Tyr-192, Arg-350          |                          |
|         |        |           |        |                          | Glu-351                   |                          |
| Linoleic acid | 5280450 | F2     | -5.4  | Thr-162, Leu-167         | Arg-202, Asp-166          |                          |
|         |        |           |        |                          | Lys-336, Glu-369          |                          |
|         |        |           |        |                          | Glu-369, Val-372          | Arg-350, Glu-351          |
|         |        |           |        |                          | Gln-193, Lys-354          |                          |
|         |        |           |        |                          | Tyr-192                   |                          |
| Palmitic acid | 985   | F3     | -5.2  | Ser-342, Glu-343         | Leu-333, Arg-288          |                          |
|         |        |           |        |                          | Glu-291, Glu-295          |                          |
|         |        |           |        |                          | Met-329, Ala-292          | Pro-227, Phe-226          |
|         |        |           |        |                          | Ile-341, Leu-228          |                          |
| Propyleneglycol monoleate | 5365625 | F4     | -5.9  | Ser-332, Tyr-222         | Lys-230, Phe-295          |                          |
|         |        |           |        |                          | Glu-295, Ile-296          |                          |
|         |        |           |        |                          | Ala-292, Arg-288          |                          |
|         |        |           |        |                          | Leu-333, Leu-228          |                          |
|         |        |           |        |                          | Met-329, Thr-229          |                          |
| β-sitosterol | 222284 | F5     | -7.9  | n/a                      | Tyr-169, Tyr-189          |                          |
|         |        |           |        |                          | Leu-167, Thr-168          |                          |
|         |        |           |        |                          | Lys-336, Arg-350          |                          |
|         |        |           |        |                          | Glu-351, Lys-354          |                          |
|         |        |           |        |                          | Gln-193, Tyr-192          |                          |
| Hexadecanoic acid, methyl ester | 8181 | F6     | -4.0  | Glu-343, Ser-342         | Leu-340, Leu-228          |                          |
|         |        |           |        |                          | Ile-341, Met-329          |                          |
|         |        |           |        |                          | Phe-226, Ala-292          |                          |
|         |        |           |        |                          | Glu-295, Pro-227          |                          |
|         |        |           |        |                          | Arg-288, Leu-333          |                          |
| 25-Oxo-27-norcholesterol | 165617 | F7     | -7.8  | Asn-375                  | Asn-335, Lys-336          |                          |
|         |        |           |        |                          | Asp-166, Arg-164          |                          |
|         |        |           |        |                          | Glu-208, Glu-207          |                          |
|         |        |           |        |                          | Val-63, Arg-202           |                          |
|         |        |           |        |                          | Glu-203, Val-372          |                          |
pathway was the highest degree among 12 signaling pathways. Reports indicated that PPAR agonists are insulin sensitizers and improve insulin resistance with T2DM patients [53]. To sum things up, a hub mechanism of SB against T2DM might be to maintain glucose homeostasis by activating PPAR signaling pathway.

5. Conclusion

*Sorghum bicolor* (SB) is rich in beneficial phytoconstituents and seen as a possible source of natural antidiabetic agents. However, in this report, its comprehensive bioactive compounds and T2DM pathways were firstly investigated using the network pharmacology. The findings of this study indicate that the antidiabetic ability of the SB could be attributed to four main compounds (β-sitosterol, campesterol, propyleneglycol monoleate, and 25-Oxo-27-norcholesterol) that were strongly related to PPAR signaling pathway. Therefore, our study suggests that the four key compounds of SB might ameliorate T2DM by activating the PPAR signaling pathway.

Supporting information

S1 Table.
(PDF)

S2 Table.
(PDF)

S3 Table.
(PDF)

S4 Table.
(PDF)
Acknowledgments

This research was acknowledged by the Department of Bio-Health Convergence, Kangwon National University, Chuncheon 24341, Republic of Korea.

Author Contributions

Conceptualization: Ki Kwang Oh.
Data curation: Ki Kwang Oh.
Formal analysis: Ki Kwang Oh.
Investigation: Ki Kwang Oh, Dong Ha Cho.
Methodology: Ki Kwang Oh.
Resources: Ki Kwang Oh.
Supervision: Dong Ha Cho.
Validation: Md. Adnan, Dong Ha Cho.
Visualization: Ki Kwang Oh.
Writing – original draft: Ki Kwang Oh.
Writing – review & editing: Md. Adnan.

References

1. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Medical Journal. Oman Medical Specialty Board; 2012. pp. 269–273. https://doi.org/10.5001/omj.2012.68 PMID: 23071876
2. Bădescu S V., Tătaru C, Kobylnska L, Georgescu EL, Zahiub DM, Zăgrean AM, et al. The association between Diabetes mellitus and Depression. Journal of medicine and life. Carol Davila—University Press; 2016. pp. 120–125. Available: /pmc/articles/PMC4863499/?report=abstract PMID: 27453739
3. Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. The Lancet Diabetes and Endocrinology. Lancet Publishing Group; 2018. pp. 69–80. https://doi.org/10.1016/S2213-8587(17)30186-9 PMID: 28847479
4. Yang W, Dall TM, Beronjia K, Lin J, Semilla AP, Chakrabarti R, et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018; 41: 917–928. https://doi.org/10.2337/dc18-0007 PMID: 29567642
5. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011; 7: 313–324. https://doi.org/10.2174/157339911797415585 PMID: 21838680
6. Robertson RP. Harmon J, Tran PO, Tanaka Y, and Takahashi H. Glucose Toxic β-cells type. 2: 581–587.
7. Lowell BB. Shulman GI. Mitochondrial Dysfuntct type. 2: 384–387.
8. Pinti M V, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Metab. 2019; 316: E268–E285. https://doi.org/10.1152/ajpendo.00314.2018 PMID: 30601700
9. Rines AK, Sharabi K, Tavares CDJ, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nature Reviews Drug Discovery. Nature Publishing Group; 2016. pp. 786–804. https://doi.org/10.1038/nrd.2016.151 PMID: 27516169
10. Vieira R, Souto SB, Sánchez-López E, Machado AL, Severino P, Jose S, et al. Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—review of classical and new compounds: Part-I. Pharmaceutics. MDPI AG; 2019. p. 152. https://doi.org/10.3390/ph12040152 PMID: 31658729
11. Tsang M-W. The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents. ISRN Endocrinol. 2012; 2012: 1–9. https://doi.org/10.5402/2012/478120 PMID: 22645689

12. Chowdhury MR, Chowdhury KH, Hanif NB, Sayeed MA, Mouah J, Mahmud I, et al. An integrated exploration of pharmacological potencies of Bischofia javanica (Blume) leaves through experimental and computational modeling. Heliyon. 2020; 6: e04895. https://doi.org/10.1016/j.heliyon.2020.e04895 PMID: 32984603

13. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Cañizo-Gómez del FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016; 7: 354. https://doi.org/10.4239/wjd.v7.i17.354 PMID: 27660695

14. Della Pepa G, Vetrani C, Vitale M, Riccardi G. Wholegrain intake and risk of type 2 diabetes: Evidence from epidemiological and intervention studies. Nutrients. MDPI AG; 2018. https://doi.org/10.3390/nu10091288 PMID: 30213062

15. Althwab S, Carr TP, Weller CL, Dweikat IM, Schlegel V. Advances in grain sorghum and its co-products as a human health promoting dietary system. Food Res Int. 2015; 77: 349–359.

16. Awika JM, Rose DJ, Simsek S. Complementary effects of cereal and pulse polyphenols and dietary fiber on chronic inflammation and gut health. Food Funct. 2018; 9: 1389–1409. https://doi.org/10.1039/c7fo02011b PMID: 29532826

17. Park JH, Lee SH, Chung IM, Park Y. Sorghum extract exerts an anti-diabetic effect by improving insulin sensitivity via PPAR-y in mice fed a high-fat diet. Nutr Res Pract. 2012. https://doi.org/10.4162/nrp.2012.6.4.322 PMID: 22977686

18. Rafi MM, Hartman TG, Das YT, Shafaie Y, Hargreaves J. Sorghum Extract Compositions. 2008.

19. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2007. pp. 687–710. https://doi.org/10.1016/j.beem.2007.09.004 PMID: 18054742

20. Lecka-Czernik B. Aleglitazar, a dual PPAR α and PPAR γ agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs. 2010; 13: 793–801. Available: https://europepmc.org/article/med/21046527

21. Gu X. Effects of Grain Sorghum Muffin on Blood Glucose and Insulin Responses in Prediabetic Men. 2014.

22. Chung IM, Kim EH, Yeo MA, Kim SJ, Seo MC, Moon HL. Antidiabetic effects of three Korean sorghum phenolic extracts in normal and streptozotocin-induced diabetic rats. Food Res Int. 2011; 44: 127–132. https://doi.org/10.1016/j.foodres.2010.10.051

23. Chung IM, Yeo MA, Kim SJ, Kim MJ, Park DS, Moon HL. Antilipidemic activity of organic solvent extract from Sorghum bicolor on rats with diet-induced obesity. Hum Exp Toxicol. 2011; 30: 1865–1868. https://doi.org/10.1177/0960327110390066 PMID: 21078773

24. Oh KK, Adnan M, Cho DH. Network pharmacology approach to bioactive chemical compounds identified from Lespedeza bicolor lignum methanol extract by GC–MS for amelioration of hepatitis. Gene Reports. 2020; 100851.

25. Oh KK, Adnan M, Cho DH. Active ingredients and mechanisms of Phellinus linteus (grown on Rosa multiflora) for alleviation of Type 2 diabetes mellitus through network pharmacology. Gene. 2020. https://doi.org/10.1016/j.gene.2020.145320 PMID: 33248199

26. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology. Nature Publishing Group; 2008, pp. 682–690. https://doi.org/10.1038/nchembio.116 PMID: 18936753

27. Wang Y, Hu B, Feng S, Wang J, Zhang F. Target recognition and network pharmacology for revealing anti-diabetes mechanisms of natural product. J Comput Sci. 2020; 45: 101186. https://doi.org/10.1016/j.jocs.2020.101186

28. Li S, Zhang B. Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chin J Nat Med. 2013; 11: 110–120. https://doi.org/10.1016/S1875-6364(13)60037-0 PMID: 23787177

29. Li H, Zhao L, Zhang B, Jiang Y, Wang X, Guo Y, et al. A network pharmacology approach to determine active compounds and action mechanisms of Ge-Gen-Qin-Lian decoction for treatment of type 2 diabetes. Evidence-based Complement Altern Med. 2014; 2014: 495840–495840. https://doi.org/10.1155/2014/495840 PMID: 24527048

30. Lipinski CA, Lombardo F, Dominy BW, Feehney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3–26. https://doi.org/10.1016/s0169-409x(00)00129-0 PMID: 11259830

31. Khanal P, Patil BM, Chand J, Naaz Y. Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19. Nat Products Bioprospect. 2020; 10: 325–335. https://doi.org/10.1007/s13659-020-00260-2 PMID: 32772313
32. Lauro FV, Francisco DC, Lenin HH, Elodia GC, Gímez-Eduardo P, Marcela RN, et al. New steroid derivative with hypoglycemic activity. Int J Clin Exp Med. 2014; 7: 3983–3991. Available: www.ijcem.com/PMID: 25550906

33. Ponnulakshmi R, Shyamaladevi B, Vijayalakshmi P, Selvaraj J. In silico and in vivo analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type-2 diabetic experimental rats. Toxicol Mech Methods. 2019; 29: 276–290. https://doi.org/10.1080/15376516.2018.1545815 PMID: 30461321

34. The Importance of Campesterol / Nutrition / Vitamins and Minerals. [cited 19 Sep 2020]. https://www. fitday.com/fitness-articles/nutrition/vitamins-minerals/the-importance-of-campesterol.html

35. The analysis of bioactive compounds in *Sorghum bicolor* against type 2 diabetes mellitus. PLOS ONE | https://doi.org/10.1371/journal.pone.0240873 December 31, 2020 23 / 24

36. Raggatt P, Whitehouse M. Substrate and inhibitor specificity of the cholesterol oxidase in bovine adrenal cortex. Biochem J. 1966; 101: 819–830. https://doi.org/10.1042/bj1010819 PMID: 16742462

37. Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes. 2010; 11: 552–555. https://doi.org/10.1111/j.1399-5448.2009.00640.x PMID: 20102528

38. Yang H, Yang L. Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. Journal of Molecular Endocrinology. BioScientifica Ltd.; 2016. pp. R93–R108. https://doi.org/10.1530/JME-15-0316 PMID: 27194812

39. Ross JS, Russo SB, Chavis GC, Cowart LA. Clinical Lipidology Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview. 2017 [cited 20 Sep 2020].

40. Nyambuya TM, Dludla P V., Nkambule BB. T cell activation and cardiovascular risk in type 2 diabetes mellitus: a protocol for a systematic review and meta-analysis. Syst Rev. 2018; 7: 167. https://doi.org/10.1186/s13643-018-0835-1 PMID: 30342529

41. Kettner A, Di Matteo M, Santoni A. Insulin potentiates FcɛRI-mediated signaling in mouse bone marrow-derived mast cells. Mol Immunol. 2010; 47: 1039–1046. https://doi.org/10.1016/j.molimm.2009.11.013 PMID: 20004975

42. Estrogen Treatment Helps To Prevent Type 2 Diabetes. [cited 20 Sep 2020]. http://www. diabetesincontrol.com/estrogen-treatment-helps-to-prevent-type-2-diabetes/

43. Li J, Rice MS, Huang T, Hankinson SE, Clevenger C V., Hu FB, et al. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 2018; 61: 2549–2560. https://doi.org/10.1007/s00125-018-4733-9 PMID: 30306190

44. Rodríguez AJ, Nunes VDS, Mastronardi CA, Neeman T, Paz-Filho GJ. Association between circulating adipocytokine concentrations and microvascular complications in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of controlled cross-sectional studies. J Diabetes Complications. 2016; 30: 357–367. https://doi.org/10.1016/j.jdiacomp.2015.11.004 PMID: 26684169

45. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. 2011; 1243: 88–102. https://doi.org/10.1111/j.1749-6632.2011.06320.x PMID: 22211895
52. Kong W, Chen N, Liu T, Zhu J, Wang J, He X, et al. Large-Scale Transcriptome Analysis of Cucumber and Botrytis cinerea during Infection. Lee Y-H, editor. PLoS One. 2015; 10: e0142221. https://doi.org/10.1371/journal.pone.0142221 PMID: 26536465

53. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2007. pp. 687–710. https://doi.org/10.1016/j.beem.2007.09.004 PMID: 18054742